Microglia and Monocytes/Macrophages Polarization Reveal Novel Therapeutic Mechanism against Stroke.
Kanazawa M, Ninomiya I, Hatakeyama M, Takahashi T, Shimohata T. · 2017
Read Microglia and Monocytes/Macrophages Polarization Reveal Novel Therapeutic Mechanism against Stroke. by Kanazawa M, Ninomiya I, Hatakeyama M, Takahashi T, Shimohata T. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5666817.txt.
Introduction
Kanazawa and co-authors present a review in the International Journal of Molecular Sciences. It proposes a cell therapy approach for stroke recovery. No drug now improves survival after the acute phase. Microglia and monocytes can take two broad states. The M1-like state drives inflammation and harm. The M2-like state protects tissue and aids repair.
M2-like cells secrete factors that rebuild tissue and vessels. They can cross into the injured brain hemisphere. Timed right, they can also calm inflammation-driven damage. The review compares the two cell types and their shifts over time. Age and sex effects on polarization get covered. Past reports on M2 therapy for both stroke types are weighed.
Catalog record
| CREATOR | Kanazawa M, Ninomiya I, Hatakeyama M, Takahashi T, Shimohata T. |
|---|---|
| YEAR | 2017 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 55 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Microglia and Monocytes/Macrophages Polarization Reveal Novel Therapeutic Mechanism against Stroke By Masato Kanazawa, Itaru Ninomiya, Masahiro Hatakeyama, Tetsuya Takahashi, Takayoshi Shimohata Published in: International Journal of Molecular Sciences DOI: 10.3390/ijms18102135 ABSTRACT Stroke is a leading cause of morbidity and mortality worldwide, and consists of two types, ischemic and hemorrhagic. Currently, there is no effective treatment to increase the survival rate or improve the quality of life after ischemic and hemorrhagic stroke in the subacute to chronic phases. Therefore, it is necessary to establish therapeutic strategies to facilitate functional recovery in patients with stroke during both phases. Cell-based therapies, using microglia and monocytes/macrophages preconditioned by optimal stimuli and/or any therapies targeting these cells, might be an ideal therapeutic strategy for managing stroke. Microglia and monocytes/macrophages polarize to the classic pro-inflammatory type (M1-like) or alternative protective type (M2-like) by optimal condition. Cell-based therapies using M2-like microglia and monocytes/macrophages might be protective therapeutic strategies against stroke for three reasons. First, M2-like microglia and monocytes/monocytes secrete protective remodeling factors, thus prompting neuronal network recovery via tissue (including neuronal) and vascular remodeling. Second, these cells could migrate to the injured hemisphere through the blood–brain barrier or choroid–plexus. Third, these cells could mitigate the extent of inflammation-induced injuries by suitable timing of therapeutic intervention. Although future translational studies are required, M2-like microglia and monocytes/macrophages therapies are attractive for managing stroke based on their protective functions. 1. INTRODUCTION Stroke is a leading cause of morbidity and mortality worldwide, and is categorized into two types, ischemic and hemorrhagic. The majority (70–80%) of stroke cases is ischemic, while intracerebral hemorrhage accounts only for 10–20% of all stroke cases [1]. Recently, several therapeutic strategies, such as thrombolytic treatments for acute ischemic stroke, were identified [2]. However, the patients who are eligible for the treatments are still between 3.4% and 5.2% of all patients with acute ischemic stroke because of the very narrow therapeutic time window [3]. To date, there is still no effective treatment that increases the survival rate or improves the quality of life after ischemic and hemorrhagic stroke [4,5,6] in the subacute to chronic phases. Currently, physical rehabilitation is considered the only effective therapeutic option to prompt functional recovery after stroke [7]. Therefore, it is necessary to establish other therapeutic strategies to facilitate the functional recovery in patients with stroke in the subacute and chronic phases. “Single-target” therapies may be insufficient because ischemic and hemorrhagic cerebral injury involves several mechanisms. It has been proposed that therapeutic approaches should target multiple cell types to promote protection and recovery [8]. Cell-based therapies using bone marrow mononuclear cells or bone marrow-derived mesenchymal stem/stromal cells may be an effective “multi-target” therapeutic strategy to facilitate functional recovery in patients with stroke during the subacute and chronic phases through pleiotropic mechanisms [8,9]. One such mechanism observed in cell-based therapies, using neural progenitor cells and mesenchymal stem cells, was the induction of axonal outgrowth and angiogenesis through the secretion of vascular endothelial growth factor (VEGF) or brain-derived neurotrophic factor (BDNF) [10,11,12,13]. In addition, although it is not known whether the recovery environment modulated by cell-based therapies is a direct effect of the administered/transplanted cells themselves, peripheral immune cells may also alter the cytokines released from the periphery into the brain parenchyma [14]. For example, human umbilical cord-blood cell therapy might induce alternations, increasing the production of anti-inflammatory interleukin-10 (IL-10), and decreasing the production of pro-inflammatory interferon-γ (INF-γ) from splenocytes [15]. Although cell-based therapies against stroke are attractive, there remain several clinical concerns, including the distinct therapeutic mechanism and efficiency with which bone marrow-derived cells cross the blood–brain barrier (BBB) [16]. Cell-based therapies using microglia and monocytes/macrophages, and any strategies targeting these cells, might be a promising therapeutic strategy because these cells are the main source of the above-mentioned growth factors in the central nervous system (CNS) [8,17]. Although several studies have demonstrated that microglia and monocytes/macrophages might deteriorate the outcome after stroke in the acute phase [4,18,19,20], these cells are known to play protective roles through tissue and vascular remodeling after stroke, during both the subacute and chronic phases [20,21,22]. The protective M2-like microglia and monocytes/macrophages exert their effect through the secretion of remodeling factors, such as VEGF, BDNF, and matrix metalloproteinase-9 (MMP-9) [23,24,25], in addition to protective cytokines, such as transforming growth factor-β (TGF-β) and IL-10 [26,27], which may facilitate anti-inflammation, axonal outgrowth, and angiogenesis after ischemic [20,21,27,28] and hemorrhagic stroke [22,29,30]. Furthermore, microglia and infiltrating macrophages constitute the predominant phagocytes removing dead cells and tissue debris for remodeling after stroke [31]. In addition, administrated microglia and monocytes/macrophages can cross the BBB, particularly in the pathological condition [32,33,34]. Therefore, cell-based therapies using microglia and monocytes/macrophages preconditioned by optimal condition and/or any therapies targeting these cells might be an ideal therapeutic strategy for stroke. In this review, we describe the pathophysiological roles of microglia and monocytes/macrophages after stroke. In addition, we briefly outline the therapeutic mechanisms of using microglia and monocytes/macrophages polarization for prompting neuronal network and angiogenesis, attenuating inflammation, and improving the therapeutic outcomes of patients with stroke. 2. THE DIFFERENCES AND SIMILARITIES BETWEEN MICROGLIA AND MONOCYTES/MACROPHAGES Microglia and monocytes/macrophages have distinct cellular origins. Microglia originate from yolk sac progenitors in the neuroepithelium, and express, in the adult brain, high levels of CX3C chemokine receptor 1 (CX3CR1), cluster of differentiation 11b (CD11b), and F4/80, low levels of CD45, and no C-C chemokine receptor type 2 (CCR2) [35]. In contrast, monocytes/macrophages originate from hematopoietic stem cells. The inflammatory monocytes/macrophages express CCR2, CD11b, Ly6C, and low levels of CX3CR1 [36]. After stroke, the release of nucleotides (ATP, UTP) from injured cells, including neurons, activates purinergic receptors on microglia and monocytes/macrophages, and leads to the production of pro-inflammatory cytokines [17]. Recently, the purinergic receptor P2Y12 (P2Y12R) has been identified as a specific marker for microglia in rodents, thus enabling their distinction from monocytes/macrophages [37]. Thus, the expression of P2Y12R might be specific for microglia, including human microglia [38,39]. However, both microglia and monocytes/macrophages express the same extent of cell surface markers (e.g., CD11b, F4/80, Iba-1) and share similar functions [40], including fundamental functions, such as phagocytosis and modulation of inflammation. 3. MICROGLIA AND MONOCYTES/MACROPHAGES ACT AS DOUBLE-EDGED SWORD AFTER STROKE The function of microglia and monocytes/macrophages changes according to the different polarization states. Previously, several studies have demonstrated that microglia and monocytes/macrophages might play harmful roles in the acute phase of ischemic [18,19,20,41] and hemorrhagic stroke [42]. This was evidenced by in vitro experiments using microglial cultures stimulated with pro-inflammatory factors, such as lipopolysaccharide (LPS), IFN-γ, or tumor necrosis factor (TNF)-α, which demonstrated the death of cultured neurons in the presence of the activated microglia (or the resulting supernatant) [43,44]. Therefore, microglia and monocytes/macrophages were thought to accelerate inflammation. However, they have also been demonstrated to exert a protective role in processes involved in neurological recovery, including neurogenesis, axonal outgrowth, synaptogenesis, angiogenesis, oligodendrogenesis, and remyelination in several CNS diseases [45,46]. Based on these findings, microglia and monocytes/macrophages act as a double-edged sword, by playing essential roles in clearing debris, inflammation, causing tissue damage, and promoting tissue healing (remodeling) [22,27,47,48]. 4. PHENOTYPIC POLARIZATION OF MICROGLIA AND MONOCYTES/MACROPHAGES AFTER STROKE The activated microglia and monocytes/macrophages have been defined as either classic (pro-inflammatory; M1-like) or alternative (anti-inflammatory or protective; M2-like)